Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 20 mg - tablet - excipient ingredients: citric acid monohydrate; sodium lauryl sulfate; butylated hydroxyanisole; croscarmellose sodium; lactose monohydrate; microcrystalline cellulose; magnesium stearate; propyl gallate; hypromellose - adults (?18 years),prevention of cardiovascular disease,ezetimibe and simvastatin tablets is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy.,primary hypercholesterolaemia,ezetimibe and simvastatin tablets is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone.,? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe and simvastatin tablets is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetimibe and simvastatin tablets is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone.,? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe and simvastatin tablets is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 20 mg - tablet - excipient ingredients: citric acid monohydrate; sodium lauryl sulfate; microcrystalline cellulose; lactose monohydrate; magnesium stearate; propyl gallate; butylated hydroxyanisole; hypromellose; croscarmellose sodium - adults (?18 years),prevention of cardiovascular disease,ezetimibe and simvastatin tablets is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy.,primary hypercholesterolaemia,ezetimibe and simvastatin tablets is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone.,? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe and simvastatin tablets is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetimibe and simvastatin tablets is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone.,? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe and simvastatin tablets is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Ireland - English - HPRA (Health Products Regulatory Authority)

zentiva k.s. - ezetimibe; atorvastatin - film-coated tablet - atorvastatin and ezetimibe

Ireland - English - HPRA (Health Products Regulatory Authority)

zentiva k.s. - ezetimibe; atorvastatin calcium trihydrate - film-coated tablet - atorvastatin and ezetimibe

Ireland - English - HPRA (Health Products Regulatory Authority)

zentiva k.s. - ezetimibe; atorvastatin calcium trihydrate - film-coated tablet - atorvastatin and ezetimibe

Ireland - English - HPRA (Health Products Regulatory Authority)

zentiva k.s. - ezetimibe; atorvastatin calcium trihydrate - film-coated tablet - atorvastatin and ezetimibe

Canada - English - Health Canada

pro doc limitee - ezetimibe - tablet - 10mg - ezetimibe 10mg - cholesterol absorption inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe

Ireland - English - HPRA (Health Products Regulatory Authority)

key pharmaceuticals ltd - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe